SG10201603946PA - Therapeutic compositions and methods involving mrna transfection - Google Patents

Therapeutic compositions and methods involving mrna transfection

Info

Publication number
SG10201603946PA
SG10201603946PA SG10201603946PA SG10201603946PA SG10201603946PA SG 10201603946P A SG10201603946P A SG 10201603946PA SG 10201603946P A SG10201603946P A SG 10201603946PA SG 10201603946P A SG10201603946P A SG 10201603946PA SG 10201603946P A SG10201603946P A SG 10201603946PA
Authority
SG
Singapore
Prior art keywords
therapeutic compositions
methods involving
mrna transfection
involving mrna
transfection
Prior art date
Application number
SG10201603946PA
Inventor
Mark C Herzberg
Karen Farnie Ross
Brent S Sorenson
Original Assignee
Mark C Herzberg
Karen Farnie Ross
Brent S Sorenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark C Herzberg, Karen Farnie Ross, Brent S Sorenson filed Critical Mark C Herzberg
Publication of SG10201603946PA publication Critical patent/SG10201603946PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201603946PA 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection SG10201603946PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361751504P 2013-01-11 2013-01-11

Publications (1)

Publication Number Publication Date
SG10201603946PA true SG10201603946PA (en) 2016-07-28

Family

ID=51167392

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201505431XA SG11201505431XA (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection
SG10201603946PA SG10201603946PA (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201505431XA SG11201505431XA (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Country Status (13)

Country Link
US (3) US20150344537A1 (en)
EP (2) EP3501551B1 (en)
JP (4) JP2016511230A (en)
KR (2) KR102119985B1 (en)
CN (1) CN105473163A (en)
AU (1) AU2014205298B2 (en)
CA (2) CA2901409C (en)
ES (1) ES2738315T3 (en)
IL (2) IL239898B (en)
NZ (1) NZ710495A (en)
PL (1) PL2943226T3 (en)
SG (2) SG11201505431XA (en)
WO (1) WO2014110366A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ710495A (en) * 2013-01-11 2019-10-25 Mark C Herzberg Therapeutic compositions and methods involving mrna transfection
CN109890403B (en) 2016-11-07 2023-06-20 明斯特威斯特法伦威廉大学 S100A8/S100A9 induced immune tolerance in neonatal subjects
CN107841508A (en) * 2017-11-29 2018-03-27 重庆市中医院 The recombinant attenuated salmonella and construction method of the element of the iron containing suppression, expression or delivery vector
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553523A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
JP6891157B2 (en) * 2018-11-15 2021-06-18 正生 池本 Functional peptide, medicine for colitis and delivery agent using it
CN114561381A (en) * 2022-03-14 2022-05-31 桂林医学院 Immune mRNA and preparation method and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797402B1 (en) * 1999-07-15 2004-03-12 Biomerieux Stelhys USE OF A POLYPEPTIDE FOR DETECTING, PREVENTING OR TREATING A CONDITION ASSOCIATED WITH A DEGENERATIVE, NEUROLOGICAL OR AUTOIMMUNE DISEASE
AU7725500A (en) * 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
WO2002022686A2 (en) * 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
DE10121254A1 (en) * 2001-04-30 2002-11-07 Switch Biotech Ag Functional assay on the activity of human MRP8/MRP14 heterodimer, for diagnosing and treating skin diseases, wounds or wound-healing disturbances with reduced quantity of the heterodimer, in particular a diabetic ulcer
WO2004089292A2 (en) * 2003-04-04 2004-10-21 The Regents Of The University Of California Immunomodulatory agents for treatment of inflammatory diseases
DE10324997A1 (en) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8 / Mrp14 inhibitors and their use for the prevention and / or treatment of hypertrophic scars and keloids
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
US7297786B2 (en) * 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
US20090305963A1 (en) * 2005-01-19 2009-12-10 Sukhatme Vikas P Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis
KR100681763B1 (en) * 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 2 A therapeutic agent comprising lipocalin 2 against cancer metastasis and methods of early diagnosis and inhibition of cancer metastasis using lipocalin 2
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
EP2167653A2 (en) * 2007-06-11 2010-03-31 University Of Vermont And State Agricultural College Treatments involving glutaredoxins and similar agents
US8916163B1 (en) * 2007-12-21 2014-12-23 Vanderbilt University Method for treating microbial infections
DE102010040153A1 (en) * 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Combination of substances for the treatment of inflammatory or infectious diseases
CA2831613A1 (en) * 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10174081B2 (en) * 2011-04-21 2019-01-08 George Mason Research Foundation, Inc. Antimicrobial peptides and uses therefore
NZ710495A (en) * 2013-01-11 2019-10-25 Mark C Herzberg Therapeutic compositions and methods involving mrna transfection

Also Published As

Publication number Publication date
JP2016511230A (en) 2016-04-14
IL262252B (en) 2020-06-30
JP2021019644A (en) 2021-02-18
NZ710495A (en) 2019-10-25
EP2943226A1 (en) 2015-11-18
KR102119985B1 (en) 2020-06-05
JP2019031521A (en) 2019-02-28
EP3501551A1 (en) 2019-06-26
IL262252A (en) 2018-11-29
WO2014110366A1 (en) 2014-07-17
JP6473729B2 (en) 2019-02-20
PL2943226T3 (en) 2019-09-30
CN105473163A (en) 2016-04-06
EP2943226B1 (en) 2019-03-13
CA2901409A1 (en) 2014-07-17
EP3501551C0 (en) 2023-06-07
KR20160031999A (en) 2016-03-23
KR102056511B1 (en) 2019-12-16
US20240166701A1 (en) 2024-05-23
SG11201505431XA (en) 2015-08-28
AU2014205298A1 (en) 2015-08-13
US20150344537A1 (en) 2015-12-03
JP6956059B2 (en) 2021-10-27
EP2943226A4 (en) 2016-11-23
CA2901409C (en) 2022-06-07
US20200231640A1 (en) 2020-07-23
IL239898B (en) 2018-10-31
US11912744B2 (en) 2024-02-27
KR20180026811A (en) 2018-03-13
CA3152721A1 (en) 2014-07-17
EP3501551B1 (en) 2023-06-07
IL239898A0 (en) 2015-08-31
ES2738315T3 (en) 2020-01-21
AU2014205298B2 (en) 2018-11-01
JP2017052781A (en) 2017-03-16

Similar Documents

Publication Publication Date Title
IL285985A (en) Therapeutic nuclease compositions and methods
HK1226301A1 (en) Modified therapeutic agents and compositions thereof
HK1222122A1 (en) Selective drug delivery compositions and methods of use
IL286759A (en) Therapeutic methods and compositions
ZA201504902B (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
EP2912178A4 (en) Super-enhancers and methods of use thereof
IL262252B (en) Therapeutic compositions and methods involving mrna transfection
EP2964235A4 (en) Antimicrobial-antibiofilm compositions and methods of use thereof
EP2884984A4 (en) Therapeutic compositions and methods
HK1220920A1 (en) Therapeutic compositions and uses thereof
EP2999474A4 (en) Therapeutic and method of use
HK1221416A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
HK1217720A1 (en) Selective delivery molecules and methods of use
HK1225645A1 (en) Pcv2b divergent vaccine composition and methods of use
HK1224307A1 (en) Protoxin-ii variants and methods of use -ii
HK1217432A1 (en) Compositions and methods for polynucleotide transfection
EP2961386A4 (en) Mirna profiling compositions and methods of use
EP2806894A4 (en) Methods and compositions for therapeutic agents
IL245529A0 (en) Rapidly disintegrating formulations and methods of use
EP2983789A4 (en) Compositions and methods for the delivery of therapeutics
EP2895186A4 (en) Therapeutic compositions and related methods
IL244537A0 (en) Novel delivery compositions and methods of using same
GB201319255D0 (en) Therapeutic compositions and methods